Effect of allopurinol on caffeine disposition in man

British Journal of Clinical Pharmacology
D M GrantW Kalow

Abstract

Caffeine (5 mg kg-1) was administered orally to two healthy, non-smoking subjects on three separate occasions--before, and during therapy with the xanthine oxidase inhibitor allopurinol at doses of either 300 or 600 mg daily. Plasma and urinary levels of methylxanthines, endogenous oxypurines and allopurinol and its metabolite oxypurinol were measured using h.p.l.c. analyses. Allopurinol treatment caused a specific, dose-dependent inhibition of the conversion of the caffeine metabolite 1-methylxanthine (1X) to 1-methyluric acid (1U). A good correlation was observed in both subjects between the urinary 1U/1X molar ratio and the ratio of endogenous urate to hypoxanthine + xanthine at the different allopurinol doses, supporting the proposal that the 1U/1X molar ratio after caffeine intake provides an in vivo index of xanthine oxidase activity in man.

References

Nov 1, 1979·Clinical Pharmacology and Therapeutics·J J GrygielD J Birkett
May 1, 1978·Clinical Pharmacology and Therapeutics·K HandeB Chabner
Mar 1, 1977·Biochemical Pharmacology·T Spector
Dec 28, 1976·Pflügers Archiv : European journal of physiology·T H Steele, J L Underwood
Jun 1, 1972·Archives of Biochemistry and Biophysics·T A KrenitskyG H Hitchings
Mar 1, 1984·Biochemical Pharmacology·W W Kutcher, D R McCalla
May 1, 1984·Proceedings of the National Academy of Sciences of the United States of America·T A KrenitskyP D Whiteman
May 1, 1983·Clinical Pharmacology and Therapeutics·D M GrantW Kalow
Apr 1, 1984·British Journal of Clinical Pharmacology·D M GrantW Kalow
Mar 1, 1983·Clinical Pharmacology and Therapeutics·D M GrantW Kalow
Jan 1, 1983·British Journal of Clinical Pharmacology·D J BirkettJ Attwood
Jul 1, 1982·Clinical Pharmacology and Therapeutics·M BonatiS Garattini
Feb 1, 1981·Clinical Pharmacology and Therapeutics·R L Manfredi, E S Vesell

❮ Previous
Next ❯

Citations

Jan 1, 1996·Journal of Clinical Pharmacology·J E TisdaleB J Zarowitz
Jan 1, 1992·European Journal of Clinical Pharmacology·L Lennard
Jan 13, 2006·European Journal of Clinical Pharmacology·Esteban Mayayo-SinuésAngel Ferrández-Longás
Dec 17, 2008·European Journal of Clinical Pharmacology·Alexander JetterUwe Fuhr
Mar 1, 1996·General Pharmacology·J O Miners, D J Birkett
Jan 1, 1995·Biomedicine & Pharmacotherapy = Biomédecine & Pharmacothérapie·I KlebovichE A Sotaniemi
May 29, 2002·Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences·Dany AnglicheauEric Thervet
Nov 30, 1999·Journal of Pediatric Gastroenterology and Nutrition·M BodaD Boda
Jan 1, 1995·British Journal of Clinical Pharmacology·L J NotarianniB W Silverman
Aug 1, 1990·Pharmacology & Toxicology·S Loft, H E Poulsen
Jun 14, 2001·Journal of Clinical Pharmacology·S al-AlaiyanA el-Yazigi
Sep 8, 2000·Clinical Pharmacokinetics·J A Carrillo, J Benitez
Jul 13, 2002·Biopharmaceutics & Drug Disposition·Aida MehmedagicOlivier Lafont
Oct 3, 1998·Clinical Pharmacology and Therapeutics·A D KashubaJ S Bertino
Oct 12, 2007·Basic & Clinical Pharmacology & Toxicology·Blanca SinuésAngel Ferrandez-Longás
Oct 10, 2008·Clinical Pharmacology and Therapeutics·M J KennedyG L Kearns
Feb 1, 1989·British Journal of Clinical Pharmacology·N R ScottM Y Morgan
Jan 1, 1992·European Journal of Clinical Pharmacology·D UllrichJ Bircher
Sep 1, 2012·Personalized Medicine·Paul Andrew BlakerJeremy David Sanderson
Jun 5, 2002·Hypertension in Pregnancy : Official Journal of the International Society for the Study of Hypertension in Pregnancy·Ilona NémethDomokos Boda

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.